Recent Quotes (30 days)

You have no recent quotes
chg | %

Neptune Technologies & Bioressources Inc  

(Public, CVE:NTB)   Watch this stock  
Find more results for NTB
0.0000
Delayed:  
CVE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 2.01 - 4.46
Open     -
Vol / Avg. 0.00/31,215.00
Mkt cap 147.24M
P/E     -
Div/yield     -
EPS -0.24
Shares 49.66M
Beta 2.05
Inst. own     -
May 23, 2013
Q4 2012 Neptune Technologies & Bioressources Inc Earnings Conference Call - 9:00AM EDT - Add to calendar
May 23, 2013
Q4 2012 Neptune Technologies & Bioressources Inc Earnings Release Add to calendar
Mar 19, 2013
Neptune Technologies & Bioressources Inc at Roth Conference
  

Key stats and ratios

Q4 (Nov '12) 2012
Net profit margin -176.98% -24.02%
Operating margin -173.27% -29.96%
EBITD margin - -25.97%
Return on average assets -80.36% -13.60%
Return on average equity -104.69% -9.23%
Employees 105 -
Carbon Disclosure Rating - -

Address

Suite 200 225 Promenade du Centropolis
LAVAL, QC H7T 0B3
Canada
+1-450-6872262 (Phone)
+1-450-6872272 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Neptune Technologies & Bioressources Inc. is a biotechnology company engaged in the research and development of extraction technologies. The Company�s main focuses is to identify marine biomasses pure from toxins, abundant and underexploited; to research, develop and commercialize technology for the extraction and stabilization of potent marine biological therapeutic agents, and to research and develop the safety and therapeutic efficacy of compounds for prevalent atherosclerotic conditions. It operates in three segments: Neptune, Acasti Pharma Inc. and NeuroBioPharm Inc. Its Neptune segment is engaged in the manufacturing and commercialization of nutraceutical products. Its Acasti Pharma segment is involved in the development and commercialization of pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharma segment is involved in the development of commercialization of pharmaceutical products for neurological diseases.

Officers and directors

Ronald Denis Independent Chairman of the Board
Henri Harland President, Chief Executive Officer, Director
Andre Godin Chief Financial Officer
Michel Chartrand Chief Operating Officer, Director
Fotini Sampalis M.D., Ph.D. Chief Global Strategy Officer
Harlan W. Waksal M.D. Director
Age: 59
Jean-Claude Debard Independent Director
Daniel Perry Independent Director